News that GlaxoSmithKline had won US regulatory approval for Requip XL sent shares in SkyePharma, which provides the technology used in the drug, up by a third on Monday.

The clearance for the Parkinson’s disease treatment provided a much-needed fillip for SkyePharma, which specialises in drug-delivery technologies. Shares in the company have fallen nearly 50 per cent since April amid concerns over its ability to refinance longstanding debt.